CARMAT Postpones Interim Financial Report Amid Receivership Challenges

CARMAT, a leading MedTech company known for its artificial heart innovation, announced the delay of its 2025 interim financial report for the period ending June 30. This decision follows ongoing receivership procedures and uncertainties surrounding the company's future.

Since July 1, 2025, CARMAT has been in receivership. The Versailles Economic Court had not received valid bids for a takeover during a recent hearing, leading to a potential conversion to liquidation by November 25. New bids are expected by November 3, but their success remains uncertain.

If no successful takeover occurs, CARMAT faces liquidation. This would likely result in shareholders losing their investment and creditors facing substantial losses. Despite financial constraints, CARMAT prioritizes patient support for its Aeson® heart device during this uncertain period.